B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S

被引：1
|
作者：
Jacob-Dolan, Catherine [1 ,2 ,3 ]
Lifton, Michelle [1 ]
Powers, Olivia C. [1 ]
Miller, Jessica [1 ]
Hachmann, Nicole P. [1 ]
Vu, Mya [2 ]
Surve, Nehalee [1 ]
Mazurek, Camille R. [1 ]
Fisher, Jana L. [1 ]
Rodrigues, Stefanie [1 ]
Patio, Robert C. [1 ]
Anand, Trisha [1 ]
Le Gars, Mathieu [4 ]
Sadoff, Jerald [4 ]
Schmidt, Aaron G. [2 ,3 ]
Barouch, Dan H. [1 ,2 ,3 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA
[2] MIT & Harvard, Ragon Inst Mass Gen, Cambridge, MA 02139 USA
[3] Harvard Med Sch, Dept Microbiol, Boston, MA 02115 USA
[4] Janssen Vaccines & Prevent BV, Leiden, Netherlands
来源：
ISCIENCE | 2024年 / 27卷 / 05期
关键词：
monoclonal antibodies; long term affinity; AFFINITY MATURATION; NEUTRALIZING ANTIBODIES; TRANSMISSION; DYNAMICS; EFFICACY; POTENCY; ESCAPE; TRIAL;
D O I：
10.1016/j.isci.2024.109716
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
The viral vector -based COVID-19 vaccine Ad26.COV2.S has been recommended by the WHO since 2021 and has been administered to over 200 million people. Prior studies have shown that Ad26.COV2.S induces durable neutralizing antibodies (NAbs) that increase in coverage of variants over time, even in the absence of boosting or infection. Here, we studied humoral responses following Ad26.COV2.S vaccination in individuals enrolled in the initial Phase 1/2a trial of Ad26.COV2.S in 2020. Through 8 months post vaccination, serum NAb responses increased to variants, including B.1.351 (Beta) and B.1.617.2 (Delta), without additional boosting or infection. The level of somatic hypermutation, measured by nucleotide changes in the VDJ region of the heavy and light antibody chains, increased in Spike -specific B cells. Highly mutated mAbs from these sequences neutralized more SARS-CoV-2 variants than less mutated comparators. These findings suggest that the increase in NAb breadth over time following Ad26.COV2.S vaccination is mediated by affinity maturation.
引用
收藏
页数：13
相关论文
共 50 条
  • [31] Association of Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barre Syndrome Reply
    Woo, Emily Jane
    Dimova, Rositsa B.
    Mba-Jonas, Adamma
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (04): : 393 - 394
  • [32] Preliminary Analysis of the Effects of Ad26.COV2.S Vaccination on CT Findings and High Intensive Care Admission Rates of COVID-19 Patients
    Negroni, Davide
    Carriero, Serena
    Passarella, Ilaria
    Siani, Agnese
    Biondetti, Pierpaolo
    Pizzolante, Antonio
    Saba, Luca
    Guzzardi, Giuseppe
    TOMOGRAPHY, 2022, 8 (05) : 2403 - 2410
  • [33] Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination
    Ashrani, Aneel A.
    Crusan, Daniel J.
    Petterson, Tanya
    Bailey, Kent
    Heit, John A.
    JAMA INTERNAL MEDICINE, 2022, 182 (01) : 80 - 83
  • [34] Comment on "Oral lichen planus following the administration of vector based COVID-19 vaccine (Ad26.COV2.S)". Authors' reply
    Troeltzsch, Matthias
    Berndt, Ronald
    Troeltzsch, Markus
    ORAL DISEASES, 2022, 28 : 2610 - 2611
  • [35] Guillain-Barre Syndrome After Ad26.COV2.S Vaccination
    Thant, Hein Linn
    Morgan, Richard
    Paese, Mario M.
    Persaud, Trevor
    Diaz, Jose
    Hurtado, Lina
    AMERICAN JOURNAL OF CASE REPORTS, 2022, 23
  • [36] Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines
    Naranbhai, Vivek
    Garcia-Beltran, Wilfredo F.
    Chang, Christina C.
    Mairena, Cristhian Berrios
    Thierauf, Julia C.
    Kirkpatrick, Grace
    Onozato, Maristela L.
    Cheng, Ju
    St Denis, Kerri J.
    Lam, Evan C.
    Kaseke, Clarety
    Tano-Menka, Rhoda
    Yang, Diane
    Pavlovic, Maia
    Yang, Wendy
    Kui, Alexander
    Miller, Tyler E.
    Astudillo, Michael G.
    Cahill, Jennifer E.
    Dighe, Anand S.
    Gregory, David J.
    Poznansky, Mark C.
    Gaiha, Gaurav D.
    Balazs, Alejandro B.
    Iafrate, A. John
    JOURNAL OF INFECTIOUS DISEASES, 2022, 225 (07): : 1141 - 1150
  • [37] Vaccine-induced pseudothrombocytopenia after Ad26.COV2.S vaccination
    Marcel Kemper
    Christoph Berssenbrügge
    Georg Lenz
    Rolf Michael Mesters
    Annals of Hematology, 2022, 101 : 927 - 928
  • [38] Vaccine-induced pseudothrombocytopenia after Ad26.COV2.S vaccination
    Kemper, Marcel
    Berssenbruegge, Christoph
    Lenz, Georg
    Mesters, Rolf Michael
    ANNALS OF HEMATOLOGY, 2022, 101 (04) : 927 - 928
  • [39] Use of Janssen Ad26.COV2.S COVID-19 vaccine (JCOVDEN) and mRNA COVID-19 vaccines in four large US national insurers
    Mayer, Sophie E.
    Fuller, Candace C.
    Haynes, Kevin
    Alam, Sarah
    Brown, Jeffrey
    Daniels, Kimberly M.
    Hawrusik, Rebecca
    Horgan, Casie E.
    Jamal-Allial, Aziza
    Johannes, Catherine B.
    Kawai, Alison Tse
    Layton, J. Bradley
    Mai, Xiaodan
    Marshall, James
    McMahill-Walraven, Cheryl N.
    Reynolds, Juliane S.
    Seals, Ryan M.
    Selvan, Mano
    Stemkowski, Stephen A.
    Wang, Florence
    Yost, Emily
    Gilsenan, Alicia W.
    Platt, Richard
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 186 - 186
  • [40] Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16-17 Years of Age
    Ruiz-Guinazu, Javier
    Le Gars, Mathieu
    Cardenas, Vicky
    Vaissiere, Nathalie
    Sadoff, Jerald
    Truyers, Carla
    Hendriks, Jenny
    Scheper, Gert
    de Groot, A. Marit
    Struyf, Frank
    Schuitemaker, Hanneke
    Douoguih, Macaya
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2024, 13 (11) : 599 - 601
12345